drugset / Trial / NCT03038620

Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks on-treatment.

Timeline

Start
2017-01
Primary completion
2020-10-13
Completion
2020-10-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 3 mg Subcutaneous